The use of treatment plan characteristics to predict patient-specific quality assurance (QA) measurement results has recently been reported as a strategy to help facilitate automated pre-treatment verification workflows or to provide a virtual assessment of delivery quality. The goal of this work is to investigate the potential of using treatment plan characteristics and linac performance metrics (i.e. quality control test results) in combination with machine learning techniques to predict the results of VMAT patient-specific QA measurements. Using features that describe treatment plan complexity and linac performance metrics, we trained a linear support vector classifier (SVC) to classify the results of VMAT patient-specific QA measurements. The 'targets' in this model were simple classes representing median dose difference between measured and expected dose distributions-'hot' if the median dose deviation was >1%, 'cold' if it was <-1%, and 'normal' if it was within ±1%. A total of 1620 unique patient-specific QA measurements were available for model development and testing. 75% of the data were used to develop and cross-validate the model, and the remaining 25% were used for an independent assessment of model performance. For the model development phase, a recursive feature elimination (RFE) cross-validation technique was used to eliminate unimportant features. Model performance was assessed using receiver operator characteristic (ROC) curve metrics. Of the ten features found to be most predictive of patient-specific QA measurement results, half were derived from treatment plan characteristics and half from quality control (QC) metrics characterizing linac performance. The model achieved a micro-averaged area under the ROC curve of 0.93, and a macro-averaged area under the ROC curve of 0.88. This work demonstrates the potential of using both treatment plan characteristics and routine linac QC results in the development of machine learning models for VMAT patient-specific QA measurements.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ab142e | DOI Listing |
JAMA Netw Open
January 2025
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.
Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.
Discov Oncol
January 2025
School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Background: Nucleolar protein 7 (NOL7), a specific protein found in the nucleolus, is crucial for maintaining cell division and proliferation. While the involvement of NOL7 in influencing the unfavorable prognosis of metastatic melanoma has been reported, its significance in predicting the prognosis of patients with Hepatocellular Carcinoma (HCC) remains unclear.
Methods: Aberrant expression of NOL7 in HCC and its prognostic value were evaluated using multiple databases, including TCGA, GTEx, Xiantao Academic, HCCDB, UALCAN, TISCH, and STRING.
Geriatr Psychol Neuropsychiatr Vieil
December 2024
Research Department, Biostatistics, Lille Catholic Hospitals, Lille, France.
The personalized prescription plan (PPP) summarizes the changes made to a patient's prescription on discharge from hospital. The aim of the present study was to evaluate 30-day medication continuity in older patients whose PPP was implemented at hospital discharge. Prospective randomized controlled trial including people aged at least 75 discharged from an acute geriatric unit.
View Article and Find Full Text PDFInt J Urol
January 2025
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Background: It was controversial to use open surgery or minimally invasive surgery (MIS) for adrenocortical carcinoma (ACC). This retrospective study aimed to evaluate the impact on prognosis between MIS and open surgery in patients with clinical stage I-II ACC.
Methods: Patients with stage I-II ACC from December 2000 to October 2022 were retrospectively studied.
Int J Urol
January 2025
Department of Urology, School of Medicine, Ankara University, Ankara, Turkey.
Objectives: To evaluate the role of neoadjuvant chemotherapy in the final treatment plan and its impact on survival in bladder cancer patients who were diagnosed with variant histology in the radical cystectomy specimen and whose diagnostic accuracy was achieved with the previous transurethral resection of the bladder specimen.
Methods: In this retrospective multicenter study, data from 221 patients across 9 centers were analyzed between January 2012 and January 2022. The primary endpoint was overall, cancer-specific, recurrence-free, and metastasis-free survival rates among patients with and without neoadjuvant chemotherapy, and the secondary endpoint was to identify independent predictors of survival.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!